Allergan settles with New York AGO in memantine immediate-release litigation
Ireland-domiciled drugmaker Allergan (NYSE: AGN) has reached an agreement with the New York State Attorney General's Office to end the litigation over the decision of subsidiary Forest Laboratories, announced in February 2014, to cease marketing and selling the now generic version of memantine immediate release tablets.
Allergan said it would discontinue its Alzheimer’s drug Namenda IR in favor of Namenda XR, which have the same active ingredient, memantine, but Namenda XR is taken once daily rather than twice. News of the settlement saw shares of Allergan – the subject of $160 billion merger negotiations with Pfizer – rise 2.8% to $320.26 on Wednesday.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze